News | May 22, 2024
AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Highly effective preservation solutions ensuring the safety and protection of personal care products
The pilot plant is focused on scaling up beverage production and will support applications
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
Connecting new production and consumption areas of chilled food by low-carbon transportation services
Receives registration of Valganciclovir powder for oral solution in Germany
The new ECO grade is made using renewable feedstock
Evinova will operate as a separate health-tech business within AstraZeneca
Subscribe To Our Newsletter & Stay Updated
